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Materials and Methods 
 
Peripheral blood or saliva samples from healthy unrelated volunteer donors were obtained by 
venipuncture or by collection of saliva using the ORAGENE-ONE collection kits (DNA Genotek 
Inc., Ottawa). In the case of blood samples, DNA was extracted by an in-house salting-out 
method. For the saliva samples, the manufacturer’s extraction method was followed. All 
participants were born in the Costa Rican Central Valley and signed an informed consent. A 
total of 153 samples from CCVP inhabitants were genotyped. The samples were typed to 
intermediate resolution by SSO or SSP methods, and samples that were HLA-B*57-positve 
were further typed by SBT in order to define the alleles to four-digit resolution.  
Introduction 
 
HLA-B*57:01 is a now a well-known pharmacogenetic marker for Abacavir hypersensitivity 
among HIV+ individuals, which can be fatal and leads to treatment failure and important 
economic costs for health systems. The utility and cost-effectiveness of the typing of this allele 
as a prospective marker has been confirmed to decrease or abolish Abacavir hypersensitivity 
reactions in these patients. However, as for other HLA alleles, there is widespread variation in 
its frequency across populations. Thus, characterization of the frequency of this marker in a 
given population is the first step towards the evaluation of the feasibility and need of 
pharmacogenetic screening for this drug.  
 
The Costa Rica Central Valley Population (CCVP) is the major population in this country. 
Approximately 60% of this country’s population lives within this region, which represents less 
than 5% of its territory. Figure 1 shows its location and a detail of its major urban centers. The 
CCVP has been used as a hub for genetic studies due to its interesting demographic and 
ethnographic characteristics. We have recently described the frequency of HLA allele groups 
in a sample of healthy volunteer donors from the CCVP. However, the high-resolution 
frequency of HLA-B*57:01 in this population has not been described yet. An important 
Caucasian component in this admixed population (Figure 2) may favor the presence of this 
allele. Consequently, in an exploratory study, we set out to determine the frequency of this 
allele in a sample of unrelated healthy donors.  
Conclusions 
 
HLA-B*57:01 is present in the CCVP at a relevant frequency and thus, it is likely that people 
that carry this allele in this population are at risk of suffering Abacavir-mediated hypersensitivity 
reactions. This is evidence towards the need for the development of pharmacogenetic testing 
among HIV-positive patients who will be receiving Abacavir as part of their treatment. However, 
clinical studies that show the relation between these reactions and this allele in the CCVP must 
be carried out.  
 
Costa Rica is the only country in the Central American subregion with universal access to 
antiretroviral therapy for people living with HIV/AIDS. In 2010, there were 165 new cases of 
AIDS and 442 cases of HIV-positivity nationwide. Every year, Costa Rica spends over $11 
million on HIV care, and more than 50% of this expenditure is due to first and second line 
antiretroviral drugs. Consequently, the Costa Rican Social Security System could benefit from 
prospective typing for this allele in view of the potential prevention of hypersensitivity reactions 
and treatment failures as well as the costs associated with them, considering the relatively 
great amount of financial resources that are invested in the treatment of these patients. 
 
We are currently continuing the definition of high-resolution HLA allele and haplotype 
frequencies for this and other Costa Rican populations in order to assess the frequency of 
other potentially clinically relevant HLA alleles among its inhabitants.  
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Table 2 Frequency of the HLA-B*57 alleles in a sample of the CCVP (2N=306) and in 
other Latin American populations. 	

Figure 1 Diagram showing the location and detail of the CCVP within Costa Rica. The 
CCVP is the major population of this country and it concentrates most of the major Costa 
Rican cities in an intermontane region of approximately 90x25 km. 
	

HLA-B*57 allele Frequency in the CCVP 
Carriers in the 
CCVP (%) 
Carriers among 
Chileans 
(Poggi H et al. 2010) 
Carriers among 
Mexicans 
(Sánchez-Girón F et al. 2011) 
Carriers among 
Cubans1 
(Middleton D et al. 
2000) 
Carriers among 
US Hispanics  
(Maiers M et al. 2007) 
HLA-B*57:01 0.0261 5.23 3.70 2.00 7.10 2.53 
HLA-B*57:02 0.0033 0.65 ND ND 0.00 0.07 
HLA-B*57:03 0.0033 0.65 ND ND 0.00 1.23 
Allele group No. Observed Frequency Homozygotes Phenotype frequency 
B*35 50 0.1634 3 30.7 
B*07 37 0.1209 1 23.5 
B*44 31 0.1013 3 18.3 
B*40 29 0.0948 2 17.6 
B*15 25 0.0817 1 15.7 
B*14 20 0.0654 0 13.1 
B*08 13 0.0425 0 8.5 
B*39 13 0.0425 0 8.5 
B*18 11 0.0359 0 7.2 
B*57 10 0.0327 0 6.5 
B*38 8 0.0261 0 5.2 
B*53 8 0.0261 1 4.6 
B*37 8 0.0261 0 5.2 
B*58 7 0.0229 0 4.6 
B*41 7 0.0229 0 4.6 
B*51 6 0.0196 0 3.9 
B*45 6 0.0196 0 3.9 
B*52 4 0.0131 0 2.6 
B*56 2 0.0065 0 1.3 
B*48 2 0.0065 0 1.3 
B*49 2 0.0065 0 1.3 
B*55 2 0.0065 0 1.3 
B*13 1 0.0033 0 0.7 
B*42 1 0.0033 0 0.7 
B*27 1 0.0033 0 0.7 
B*50 1 0.0033 0 0.7 
B*73 1 0.0033 0 0.7 
Total :   306 1.0000 11 
Table 1 HLA-B allele groups identified in a sample of the CCVP (2N=306). 	

Results 
 
HLA-B*57 alleles were present in a 6.5% of the subjects (Table 1). Moreover, an HLA-B*57:01 
carrier frequency of 5.23% (allele frequency of 2.61%) was determined in this sample. Table 2 
shows the frequencies of HLA-B*57 alleles in this sample. This frequency is relatively high in 
comparison to reports from other populations in Latin America. These results suggest that there 
is a considerable frequency of HLA-B*57:01 in the CCVP and that pharmacogenetic testing for 
HIV+ patients who are going to receive Abacavir-based treatment schemes is likely to benefit 
the security of this therapy. According to WHO data, we hypothesize that some 200,000 
persons in this country would be susceptible to Abacavir-induced hypersensitivity, and that 
some 15,000 HIV+ people living in Costa Rica could benefit from prospective HLA-B*57:01 
genotyping.  
Figure 2 The CCVP has an important Caucasian component. Principal Coordinates 
Analysis (PCO, 59.1% cumulative variance) of the CCVP and 50 ancestral populations from 
Sub-Saharan Africa (upper left quadrant), Iberia (lower left quadrant) and America (right 
quadrants) based on 47 HLA-A and HLA-B allele group frequencies. 	

1 Cuban Caucasians. ND, non determined. 
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